The North America Sleep Apnea Devices Market was valued at $38.4 Million in 2025 and projected to reach to $61 Million by 2030, representing a compound annual growth rate of 6.8%. North America's sleep apnea devices market is poised for sustained growth driven by rising obesity rates, aging demographics, and increased awareness of sleep disorders' health impacts.
The United States commands the North American sleep apnea devices market with a valuation of $4,708.6 million, representing the largest regional market globally and driving innovation in diagnostic and therapeutic technologies.
North America's sleep apnea devices market is projected to grow from $38.4 million in 2025 to $61.0 million by 2030, with a CAGR of 6.8%, outpacing many developed regions due to high healthcare spending and disease awareness.
Canada contributes $964.2 million to the regional market, reflecting robust healthcare infrastructure, government reimbursement policies, and increasing diagnosis rates of obstructive sleep apnea across the population.
North America benefits from cutting-edge medical device manufacturing, strong regulatory frameworks (FDA approval), and high patient compliance rates, positioning the region as a hub for sleep apnea device innovation and adoption.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ORAL APPLIANCES (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 7.6% from 2025 to 2030 |
| Largest Segment | THERAPEUTIC DEVICES (Product) |
| Market Size Base Year (Billions) | ~USD 6.95 (2025) |
| Revenue Forecast (Billions) | ~USD 10.03 (2030) |
| Segments Covered | Product, Type |
2 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| HENRY SCHEIN | United States | Public Company | Therapeutic – Oral Appliances,Therapeutic – PAP Devices (CPAP, APAP, BPAP),Therapeutic – Masks and Consumables, |
| ROSSMAX INTERNATIONAL LTD | Taiwan | Public Company | Therapeutic – PAP (CPAP, APAP, BPAP),Therapeutic – Oral Appliances,Therapeutic – Masks, |
| SANOFI | Spain | Public Company | Therapeutic – PAP (CPAP, APAP, BPAP),Therapeutic – Oral Appliances,Therapeutic – Masks, |
| DANAHER CORPORATION | United States | Public Company | Therapeutic – PAP (CPAP, APAP, BPAP),Therapeutic – Oral Appliances,Therapeutic – Masks, |
| RESMED | United States | Public Company | Therapeutic – PAP devices (CPAP, APAP, BPAP),Therapeutic – Masks and interfaces,Therapeutic – Oral appliances, |
| KONINKLIJKE PHILIPS N.V. | Netherlands | Public Company | Therapeutic – PAP (CPAP, APAP, BPAP),Therapeutic – Masks and Interfaces,Therapeutic – Oral Appliances, |
| FISHER & PAYKEL HEALTHCARE LIMITED | New Zealand | Public Company | Therapeutic – PAP devices (CPAP, APAP, BPAP),Therapeutic – Masks and interfaces,Therapeutic – Oral appliances, |
| INSPIRE MEDICAL SYSTEMS, INC. | United States | Public Company | Therapeutic – Neurostimulation System (competes with PAP/Oral Appliances/Masks),Diagnostic-Linked Services (competes with PSG/Home Sleep Testing/Oximeter adjacencies), |
| SOMNOMED | Australia | Public Company | Therapeutic – Oral Appliances (SomnoDent portfolio, SomMorning Repositioner, SomnoBrux),Adjacencies – Cleaning and maintenance (SomTabs) and related accessories,Non-OSA dental protection (SomnoBrux-only use cases), |
| COMPUMEDICS LIMITED | Australia | Public Company | Diagnostic – PSG Systems (lab-based and ambulatory),Diagnostic – Home Sleep Testing & Wearables,Diagnostic – Oximetry and Ancillary Monitoring, |
| BMC | United States | Private Company | Therapeutic Devices (PAP, Oral Appliances, Masks),Diagnostic Devices (PSG, Home Sleep Testing, Oximeter),Healthcare IT / Workflow Enablement for Sleep Care, |
| PROSOMNUS SLEEP TECHNOLOGIES | United States | Private Company | Therapeutic – Oral Appliances,Therapeutic – PAP (CPAP, APAP, BPAP),Therapeutic – Masks, |
Henry Schein is a publicly traded United States company founded in 1932 with 25,000 employees.
Rossmax International Ltd is a publicly traded company based in Taiwan, founded in 1988.
Sanofi is a publicly traded pharmaceutical company based in Spain, founded in 1994 with 74,846 employees.
Danaher Corporation is a publicly traded United States company founded in 1969 with 59,000 employees.
ResMed is a publicly traded United States company founded in 1989 with 10,600 employees.
Koninklijke Philips N.V. is a publicly traded Dutch company founded in 1891 with 64,317 employees.
Fisher & Paykel Healthcare Limited is a publicly traded New Zealand company founded in 1934 with 7,396 employees.
Inspire Medical Systems, Inc. is a publicly traded United States company founded in 2007 with 1,333 employees.
SomnoMed is a publicly traded Australian company founded in 1987 with 300 employees.
Compumedics Limited is a publicly traded Australian company founded in 1987 with 175 employees.
BMC is a United States-based private company founded in 1980 with 6,700 employees.
ProSomnus Sleep Technologies is a United States-based private company founded in 2016 with 136 employees.
| Country | 2025 size (native) |
|---|---|
| US | USD 4708.6 Million |
| Canada | USD 964.2 Million |
–Rest Of GCC Countries sleep apnea devices market is estimated at $38.4 million in 2025 and is projected to reach $61.0 million by 2030.
–Rest Of GCC Countries is expected to grow at a compound annual growth rate (CAGR) of 6.8% from 2025 to 2030.
–Rest Of GCC Countries market growth is driven by improved healthcare infrastructure, rising healthcare awareness, increasing prevalence of sleep disorders, and growing disposable incomes enabling device adoption.
–Rest Of GCC Countries shows strong demand for CPAP devices, BiPAP systems, and emerging alternative therapeutic solutions for obstructive sleep apnea treatment.
–Rest Of GCC Countries grows at 6.8% CAGR, slightly below the global average of 7.6%, reflecting regional market maturity and healthcare development dynamics.
The study analyzes key market dynamics, such as drivers, opportunities, restraints, challenges, and key player strategies. To track company developments such as acquisitions, product launches and approvals, expansions, agreements, and partnerships of the leading players, the competitive landscape of the sleep apnea devices market is analyzed to evaluate market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. The market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
The four steps involved in estimating the market size are
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 1 million, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION |
|---|---|
| SOMNOmedcis AG (Germany) | Country Manager |
| ResMed (US) | Regional Sales Manager |
Both top-down and bottom-up approaches were used to estimate and validate the total size of sleep apnea devices in the market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Sleep apnea is a prevalent sleep disorder that is frequently undiagnosed, yet it poses significant health risks. This condition is characterized by intermittent cessation of breathing, which can last from several seconds to minutes, or by irregular breathing patterns. The most predominant form is obstructive sleep apnea (OSA), where anatomical or physiological obstructions impede airflow during sleep. Continuous positive airway pressure (CPAP) devices are commonly used to deliver air at elevated pressure through the nasal passages, effectively counteracting upper airway obstructions and facilitating normal respiration. These interventions are crucial for mitigating the associated morbidities linked with untreated sleep apnea.
Full forecast, segment splits, and company analysis for all Sleep Apnea Devices Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report